February 5, 2019, PLLR News
Concealment of Pradaxa’s risks
The family and estate of a woman who died from bleeding sued the maker of Pradaxa, alleging that the defendant misrepresented and concealed the bleeding risk that the drug posed. Suit also alleged that there was no way to reverse the drug’s anticoagulant effect. The jury awarded $1.25 million, including $1 million in punitive damages. Knight v. Boehringer Ingelheim Pharms., Inc.
Betty Knight suffered from atrial fibrillation. She took the anticoagulant warfarin but was interested in switching to a different medication with a less-demanding monitoring regimen. When she was 82, she began taking Pradaxa. She became over-anticoagulated, resulting in gastrointestinal bleeding and necessitating multiple hospitalizations. Knight later died from bleeding resulting from the anticoagulation.
Knight’s family and estate sued Boehringer Ingelheim Pharmaceuticals, Inc., alleging fraud. Among other things, the plaintiffs argued that the defendant misrepresented and concealed the bleeding risk posed by Pradaxa, especially in patients with impaired renal function. The plaintiffs also asserted that there was no way to reverse Pradaxa’s anticoagulant effect.
The jury awarded $1.25 million, including $1 million in punitive damages.
Citation: Knight v. Boehringer Ingelheim Pharms., Inc., No. 3:15-cv-6424 (S.D. W. Va. Oct. 18, 2018).
Plaintiff counsel: AAJ members C. Andrew Childers, Emily T. Acosta, and Russell Abney, all of Atlanta; AAJ member Harry Bell Jr., Charleston, W. Va.; AAJ member Lisa Causey-Streete and Robert Salim, both of Natchitoches, La.; and AAJ member Neal Moskow, Fairfield, Conn.